Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

Similar articles for PubMed (Select 19328563)

1.

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N.

Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.

PMID:
19328563
2.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
3.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
4.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

5.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
6.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

7.

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Diamond GA, Bax L, Kaul S.

Ann Intern Med. 2007 Oct 16;147(8):578-81. Epub 2007 Aug 6.

PMID:
17679700
8.

Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

Monami M, Marchionni N, Mannucci E.

Diabetes Res Clin Pract. 2008 Oct;82(1):48-57. doi: 10.1016/j.diabres.2008.08.002. Epub 2008 Sep 4.

PMID:
18775581
9.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.

Am J Ther. 2008 Nov-Dec;15(6):506-11. doi: 10.1097/MJT.0b013e318167180c.

PMID:
19127132
10.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
11.

Cardiovascular safety of rosiglitazone.

Krall RL.

Lancet. 2007 Jun 16;369(9578):1995-6. No abstract available.

PMID:
17574083
12.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
13.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Singh S, Loke YK, Furberg CD.

JAMA. 2007 Sep 12;298(10):1189-95.

PMID:
17848653
14.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
15.

The rosiglitazone meta-analysis.

McCullough PA, Lepor NE.

Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Review. No abstract available. Erratum in: Rev Cardiovasc Med. 2007 Summer;8(3):174.

PMID:
17603430
16.

[Rosiglitazone: no increase in cardiovascular mortality].

Jazet IM, Meinders AE.

Ned Tijdschr Geneeskd. 2009;153:A942. Dutch.

PMID:
19930745
17.

[Rosiglitazone--statistics for benefits and problems].

Hjelmesaeth J, Røislien J.

Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3. Norwegian. No abstract available.

18.

Rosiglitazone and cardiovascular risk.

Mannucci E, Monami M, Marchionni N.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40. No abstract available.

PMID:
17806136
19.

Cardiovascular risk of rosiglitazone: another perspective.

Waksman JC.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. Review.

PMID:
19000361
20.

Rosiglitazone and cardiovascular risk.

Diamond GA, Kaul S.

N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. No abstract available.

PMID:
17806135
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk